oalib

OALib Journal期刊

ISSN: 2333-9721

费用:99美元

投稿

匹配条件: “Flourish Itulua-Abumere” ,找到相关结果约4条。
列表显示的所有文章,均可免费获取
第1页/共4条
每页显示
Should there be Specific Policies to Protect the Welfare of Older People in Britain?
Flourish Itulua-Abumere
Open Access Journal of Science and Technology , 2013, DOI: 10.11131/2013/100003
Abstract: Older people have always been a major focus for social policy and because the UK is an ageing society, their importance to the subject is likely to increase further. Like other modern welfare systems, the British welfare state originated in pension provision for older people and totally this group are the main users of the health and social services and the main recipients of social security spending. Compared with unemployed people and lone parents, older people are often viewed as a group that “deserves” specific social policy and especially, social security. However, it is sometimes said that the true test of a civilized society is how it treats its older and vulnerable groups. Despite this group's position as one of the most deserving of welfare, there are still widespread awareness of the many negative images of old age. In common with other western societies, Britain is a country in which age discrimination, or ageism, is widespread (Alcock et al, 2006).
Anorexia Nervosa and Bulima Nervosa Critical Analysis of It's Treatment: Implications and Interventions
Flourish Itulua-Abumere
Open Access Journal of Science and Technology , 2013, DOI: 10.11131/2013/100007
Abstract: The diagnostic consideration of the eating disorders anorexia nervosa and bulimia nervosa has been given much focus over the last two decades than previously, as clinicians have become more aware of the frequency of these disorders and the difficulties associated with their treatment. Anorexia nervosa and bulimia nervosa as known in the DSM-IV as eating disorders are characterized by physically and/or psychologically harmful eating patterns. Although the psychological explanation of what we now call anorexia nervosa have been known about for centuries, it has only recently attracted much interest, due to greater public knowledge and increased incidence (according to Gross and MclLveen 2006, the latter claim has been disputed). Most people suffering from anorexia nervosa and bulimia nervosa start by fasting. Anorexia nervosa is a deliberate self-starvation. A person whose body weight is less than expected for his or her body height and weight is considered to be anorexic. In contract, bulimia involves binge eating a large quantity of food followed by purging by self-induced vomiting, enemas, laxatives, or diuretics.
Bevacizumab vs. Ranibizumab in Preserving or Improving Vision in Patients with Wet, Age-Related Macular Degeneration: A Cost-effectiveness Review
Chukwuemeka C. Nwanze, Abumere Akinwale and Ron A. Adelman
Clinical Medicine Insights: Therapeutics , 2012, DOI: 10.4137/CMT.S7439
Abstract: Objective: To evaluate the cost-effectiveness of monthly and as-needed dosing protocols using ranibizumab or bevacizumab for the treatment of neovascular age-related macular degeneration (AMD), when the treatment costs of severe ocular and systemic adverse events are considered. Methods: A Markov model was developed to assess the cost effectiveness of each of the following protocols: monthly ranibizumab, monthly bevacizumab, as-needed ranibizumab and as-needed bevacizumab. Direct costs and utilities were assessed from the perspective of a third-party payer or an insurance company. Cost effectiveness was evaluated in 2011 US dollars per quality-adjusted life year (QALY). Results: Considering the treatment costs of severe medical and ocular adverse events, the cost effectiveness of each protocol is as follows: monthly ranibizumab $63,333/QALY, ranibizumab as needed $18,571/QALY, bevacizumab monthly $2,676/QALY and bevacizumab as needed $3,333/QALY. Sensitivity analysis of the treatment costs of medical and ocular adverse events demonstrated minimal impact on relative cost-effectiveness. Conclusion: At current prices, monthly bevacizumab is the most cost-effective anti-VEGF AMD treatment protocol. Ranibizumab is as cost effective as bevacizumab at a maximum price of $158 per dose.
Bevacizumab vs. Ranibizumab in Preserving or Improving Vision in Patients with Wet, Age-Related Macular Degeneration: A Cost-effectiveness Review
Chukwuemeka C. Nwanze,Abumere Akinwale,Ron A. Adelman
Clinical Medicine Insights: Therapeutics , 2012,
Abstract:
第1页/共4条
每页显示


Home
Copyright © 2008-2017 Open Access Library. All rights reserved.